Showing 2391-2400 of 5696 results for "".
- Nominations Now Being Accepted for NORA Awardshttps://modernod.com/news/nominations-now-being-accepted-for-nora-awards/2480704/Nominations are now being accepted by the Neuro-Optometric Rehabilitation Association, International (NORA) for the following awards, which acknowledge individuals and organizations for important contributions to the area of neuro-optometric rehabilitation. The Advancement
- Apellis' Pegcetacoplan Showed Continuous Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-pegcetacoplan-showed-continuous-and-clinically-meaningful-effects-at-month-18-in-phase-3-derby-and-oaks-studies-for-geographic-atrophy-ga/2480701/Apellis Pharmaceuticals announced longer-term data from the phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for t
- Lumibird Medical Launches New Website Dedicated to Laser Therapies for Each Glaucoma Stagehttps://modernod.com/news/lumibird-medical-launches-new-website-dedicated-to-laser-therapies-for-each-glaucoma-stage/2480684/Lumibird Medical announced the launch of its new website: www.glaucoma-laser-assisted-solutions.com, which details the treatment options at every stage of the disease paradigm: 1. SLT - A first-line treatment for g
- Fera Pharmaceuticals Obtains Orphan Drug Designation from the FDA for Naproxcinod for the Treatment of Sickle Cell Diseasehttps://modernod.com/news/nicoxs-partner-fera-pharmaceuticals-obtains-orphan-drug-designation-from-the-us-fda-for-naproxcinod-for-the-treatment-of-sickle-cell-disease/2480673/Nicox SA and Fera Pharmaceuticals announced that the FDA has granted Orphan Drug Designation for naproxcinod for the treatment of sickle cell disease, which affects an estimated 100,000 Americans. Naproxcinod is a nitr
- TearSolutions Meets with FDA and Announces Next Steps in the Development of Lacripephttps://modernod.com/news/tearsolutions-meets-with-fda-and-announces-next-steps-in-the-development-of-lacripep/2480661/TearSolutions, the developer of a replacement therapy for the treatment of dry eye disease (DED) called Lacripep, announced that in late 2021 it received official minutes from a Type C meeting with the FDA regarding the development of Lacripep for the treatment of DED and is planni
- Italian Patients Receive Samsara Vision’s SING IMT, a New Technology for Age-Related Macular Degenerationhttps://modernod.com/news/italian-patients-receive-samsara-visions-sing-imt-a-new-technology-for-age-related-macular-degeneration/2480658/Samsara Vision announced the first three successful clinical cases in Italy using its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) for people living with late-stage, age-related macular degeneration (AMD). The SING IMT was successfully implanted in patients
- Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conferencehttps://modernod.com/news/clearside-biomedicals-suprachoroidal-injection-platform-featured-at-the-angiogenesis-exudation-and-degeneration-2022-virtual-conference/2480642/Clearside Biomedical announced that multiple oral presentations on Clearside’s SCS injection platform featuring the SCS Microinjector were given at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12,
- FCI Ophthalmics Announces FDA Clearance of Oculid Implantable and External Eyelid Weights for the Treatment of Lagophthalmoshttps://modernod.com/news/fci-ophthalmics-announces-fda-clearance-of-oculid-implantable-and-external-eyelid-weights-for-the-treatment-of-lagophthalmos/2480641/FCI Ophthalmics announced <
- Regenxbio Presents Positive Interim Data From Phase 2 ALTITUDE Trial of RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-presents-positive-interim-data-from-phase-3-altitude-trial-of-rgx-314-for-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery/2480639/Regenxbio announced additional positive interim data from the ongoing phase 2 ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data is being presented at the Angiogene
- Global Eye Health Body Unites With Novartis to Strengthen Eye Health in Africahttps://modernod.com/news/global-eye-health-body-unites-with-novartis-to-strengthen-eye-health-in-africa/2480626/The International Agency for the Prevention of Blindness (IAPB) has joined together with Novartis in a partnership to strengthen eye health in Sub-Saharan Africa. The new 3-year relationship will support effective policy dialogue, planning, and implementation of eye health services in the re